In agreement with the results of previous studies, a 6-month chemotherapy treatment with anthracyclines and/or anti-HER2 therapy considerably reduced GLS in the whole cohort of women with breast cancer who were undergoing chemotherapy, while an almost 20% of the cohort experienced CTRCD. Here, ERBB2 is linked to breast carcinoma.